More Deals Like Loxo On The Cards As Bayer Ups Ante In Oncology

Bayer's head of pharma Dieter Weinand chats to Scrip on the sidelines of the company's 2017 annual results conference in Leverkusen, Germany, about putting more skin in the game this time around as the second wave of immuno-oncology innovation spills into the market.  

Bayer 2017 FY Conference
L-R: Dieter Weinand, Kemal Malik and Werner Baumann at Bayer's annual results conference in Leverkusen • Source: Scrip/LEllis

Bayer AG has high hopes to be a key player as next generation immuno-oncology candidates approach the market; successfully launching larotrectinib as soon as possible with its partner Loxo Oncology Inc. is a first major test for Bayer's IO outlook.

The German big pharma is also looking for external development candidates to supplement its pipeline as its key growth products,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer